A Study of Continuous Oral Contraceptives and Doxycycline

Not Applicable

Completed

Conditions: Contraceptives, Oral

Interventions: Drug: placebo daily
Drug: Lybrel
Drug: Oracea
Drug: Subantimicrobial doxycycline daily
Drug: Placebo
Drug: Doxycycline
Drug: Doxycycline 100bid x5 days at the time of bleeding

Registration Number: NCT00480532

Lead Sponsor: Oregon Health and Science University

Brief Summary: The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug, doxycycline, is an antibiotic used commonly for many conditions (i.e. acne, Chlamydia infections, pneumonia) and can be safely used on a daily basis. Doxycycline has been shown to decrease unplanned vaginal bleeding in progestin-only contraception but has not been studied in combined hormonal contraception.

Detailed Description: We intend to conduct a prospective, randomized, placebo controlled, double blind study at Oregon Health and Science University. This study will be conducted over four 28-day cycles (112 days of active COC hormone). All women enrolled in the study will take the same daily low dose COC. This protocol will be divided into two studies, a bleeding study and an endometrial biopsy study, each with two treatment arms; typical dose doxycycline (Arm 1), and controlled release subantimicrobial dose doxycycline (CRSD)(Arm 2).

The first arm (Arm 1) of this study will constitute the typical dose doxycycline arm. In this arm, there will be two study groups. Group 1, the treatment group, will take doxycycline 100 mg orally twice a day for five days starting on the first day of bleeding if breakthrough bleeding occurs. The control group will take a placebo orally twice a day for five days starting on the first day of bleeding if breakthrough bleeding occurs. After three months, both groups will stop doxycycline (or placebo) and will continue on a COC alone for the remaining 28 days of the study.

The second arm (Arm 2) of the study will constitute the controlled release subantimicrobial dose doxycycline (CRSD doxycycline)arm. Subjects in this arm of the study will be divided into Group 3 and Group 4. Group 3 will take CRSD doxycycline (40mg) daily for three months. Group 4 will take a daily placebo. Similarly to the first arm of the trial, after three months, both groups will stop doxycycline (or placebo) and will continue in a COC alone for the remaining 28 days of the study.

This study also includes a endometrial biopsy sub-study: At the time of recruitment we will identify participants who are willing to undergo endometrial biopsy during the study period. These subjects will constitute a separate cohort who will enroll in the prospective, randomized, double blind, placebo controlled endometrial biopsy study.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 131

Inclusion Criteria

General good health
Willing and able to agree to randomization and sign informed consent
Currently having regular menstrual cycles (24-36 days), with combined cyclic hormonal method (COCs, Nuva Ring, Ortho Evra), without intermenstrual bleeding in last 2 years.

Exclusion Criteria

Intrauterine device (IUD) in place
Abnormal pap smear that has not been treated or followed up
Those with hypersensitivity reactions to doxycycline or any of the tetracyclines
Use of depomedroxyprogesterone acetate within 9 months of the start of the study.
Use of hormonal medications (excluding cyclic contraceptives and plan B) within 2 months of the start of the study.
Any one unwilling to keep a daily menstrual diary or otherwise unwilling to follow the study criteria
Currently taking medications that interfere with COCs (rifampin, carbamazepine, St. Johns wort)
Currently has a progestin implant
Positive Gonorrhea or Chlamydia cultures at enrollment examination
Smoking more than 5 cigarettes per month
Any medical condition that is a contraindication to the use of COCs in accordance with product labeling including:
- History of thrombophlebitis, deep venous thrombosis, thrombogenic vasculopathies, thrombogenic rhythm disorders or thromboembolic disorders
- Current or past history of cerebrovascular or coronary artery disease
- Scheduled major surgery in the next six months with prolonged immobilization
- Diabetes with vascular involvement
- Headache with focal neurologic symptoms
- Uncontrolled hypertension
- Suspected or known carcinoma of the breast or personal history of breast cancer
- Carcinoma of the endometrium or other known or suspected estrogen dependent neoplasms
- Undiagnosed genital bleeding
- History of cholestatic jaundice of pregnancy or cholestatic jaundice with prior oral contraceptive use
- Hepatic adenoma or carcinoma or active liver disease if liver function has not returned to normal
- Known or suspected pregnancy
- Hypersensitivity to estrogen or progesterone containing products

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo daily	placebo daily	-
placebo bid x 5 days	Lybrel	-
Subantimicrobial doxycycline daily	Subantimicrobial doxycycline daily	-
Doxycycline 100bid x5 days	Lybrel	-
Doxycycline 100bid x5 days	Doxycycline 100bid x5 days at the time of bleeding	-
placebo bid x 5 days	Placebo	-
Doxycycline 100bid x5 days	Doxycycline	-
Subantimicrobial doxycycline daily	Oracea	-

Primary Outcome Measures

Name	Time	Method
Differences in Bleeding Patterns Between Study Groups.	The outcome was also assessed for day 1 to 84	number of days of bleeding and spotting, self reported on calendar

Secondary Outcome Measures

Name	Time	Method
Subject Satisfaction.	Assessed on day 112 of the study (the end of the study period). This outcome does not represent a change from baseline. It was assessed at the end of the study period.	measured using 100 mm visual analog scale. anchors of "not at all satisfied" (0mm) "extremely satisfied" (100mm)
Subject Compliance	Assessed on day 112 of the study (the end of the study period). The outcome reflects the number of subjects who did not miss pills during the entire 112 day study. It does not represent a change from baseline.	measured by self report of pill intake on daily diary (yes/no), and reported as percentage with no missed pills over entire study